{"id":844,"date":"2021-02-12T10:15:45","date_gmt":"2021-02-12T09:15:45","guid":{"rendered":"https:\/\/ago-ovar.de\/profile\/published-trials\/"},"modified":"2026-04-08T14:52:54","modified_gmt":"2026-04-08T12:52:54","slug":"published-trials","status":"publish","type":"page","link":"https:\/\/ago-ovar.de\/en\/profile\/published-trials\/","title":{"rendered":"Published Trials"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.20.2″ custom_margin=”||164px|||” custom_padding=”0px||0px||false|false” sticky_position=”top” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.0″ text_font=”||||||||” text_font_size=”18px” link_line_height=”1.8em” global_colors_info=”{}”]<\/p>\n

Primary Therapy<\/a> | Relapse Therapy<\/a> | Uterus<\/a> | Vulva<\/a> | Cervix<\/a> | Surgical Issues<\/a> | Translational Focus<\/a> | QS-Ovar<\/a> |Other Publications<\/a> | GCIG Rare Tumor Working Group<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ specialty=”on” _builder_version=”4.16″ background_color=”#e0edf9″ global_colors_info=”{}”][et_pb_column type=”3_4″ specialty_columns=”3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_row_inner _builder_version=”4.16″ custom_padding=”||13px|||” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Published Trials<\/h1>\n

[\/et_pb_text][et_pb_text module_id=”primaer” _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Primary disease<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 1\/2<\/h3>\n

Phase I\/II study of the combination of carboplatin and paclitaxel as first-line therapy patients with advanced epithelial ovarian cancer<\/p>\n

A. du Bois, H.-J. L\u00fcck, T. Bauknecht, V. M\u00f6bus, H. Bochtler, K. Diergarten & H.-G. Meerpohl<\/p>\n

Annals of Oncology 8: 335-361 (1997)[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 3<\/h3>\n

A Randomized Clinical Trial of Cisplatin\/Paclitaxel Versus Carboplatin\/Paclitaxel as First-Line Treatment of Ovarian Cancer<\/p>\n

du Bois A, L\u00fcck H.-J, Meier W, Adams H-P, M\u00f6bus V, Costa S, Bauknecht T, Richter B, Warm M, Schr\u00f6der W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, for the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) Ovarian Cancer Study Group<\/p>\n

J Natl Cancer Inst 2003; 95:1320-30<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 4<\/h3>\n

First-line chemotherapy with epirubicin, paclitaxel, and Carboplatin (ET-Carbo) for advanced ovarian carcinoma. A phase I\/II study of the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) Ovarian Cancer Study Group<\/p>\n

A du Bois, HJ L\u00fcck, T Bauknecht, W Meier, B Richter, J Pfisterer, J Quaas, W Kuhn<\/p>\n

J Clin Oncol 17: 46-51, 1999[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 5<\/h3>\n

Addition of epirubicin as third drug to carboplatin-paclitaxel in firstline treatment of advanced ovarian cancer. …<\/p>\n

du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats Jean-Claude, Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S, Schroeder W, Kimmig R, Pujade-Lauraine E for AGO-OVAR and GINECO<\/p>\n

J Clin Oncol 24: 1127-1135[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 6<\/h3>\n

Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I\/II trial of the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group<\/p>\n

Pfisterer J, du Bois A, Wagner U, Quaas J, Blohmer JU, Wallwiener D and Hilpert F<\/p>\n

Gynecologic Oncology 92 (2004) 949-956[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 7<\/h3>\n

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer<\/p>\n

Intergroup Trial of the AGO-OVAR and GINECO<\/p>\n

Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, St\u00e4hle A, Jackisch C, Hardy-Bessard AC, M\u00f6bus V, Quaas J, Richter B, Schr\u00f6der W, Geay JF, L\u00fcck HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E for the AGO-OVAR and GINECO<\/p>\n

J Natl Cancer Inst 2006; 98:1036-1045[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 8<\/h3>\n

A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)<\/p>\n

du Bois A, Belau A, Wagner U, Pfisterer J , Schmalfeldt B, Richter B, St\u00e4hle A, Jackisch C, Lueck H-J, Schroeder W, Olbricht S, Elser G and for the Arbeitsgemeinschaft Gyneaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)<\/p>\n

Gynecol Oncol 96 (2005) 444-451[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 9<\/h3>\n

Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer<\/p>\n

du Bois A, Herstedt J, Hardy-Bessard A-C, M\u00fcller H-H, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J<\/p>\n

J Clin Oncol 28: 4162-4169 (2010)[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 10<\/h3>\n

Abagovomab as Maintenance Therapy in Patients with Epithelial Ovarian Cancer (MIMOSA Study): A Phase III Trial of the AGO OVAR,
\nCOGI, GINECO, and GEICO – The MIMOSA Study<\/p>\n

Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J<\/p>\n

J Clin Oncol 2013: 1554-1561[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 11<\/h3>\n

A Phase 3 Trial of Bevacizumab in Ovarian Cancer<\/p>\n

Perren, TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, St\u00e4hle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar M KB, Oza AM, for the ICON7 Investigators<\/p>\n

N Engl J Med 2011;365:2484-96<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial<\/p>\n

Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T<\/p>\n

Lancet Oncol 2013;14: 236-243[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial<\/p>\n

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon T-W, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MKB, Perren TJ, for the ICON7 trial investigators<\/p>\n

Lancet Oncol 2015;16:928-36[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 11t<\/h3>\n

Specialized histopathological second assessment of advanced ovarian cancer<\/span><\/span><\/span><\/p>\n

S. Kommoss, J. Pfisterer, A. du Bois, D. Schmidt, F. Kommoss<\/p>\n

Pathologe 2014, 35:355-360<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtype<\/p>\n

Kommoss S, Winterhoff B, Oberg AL, Konecny G, Wang C, Riska SM, Fan JB, Maurer MJ, Craig A, Shridhar V, Kommoss F, du Bois A, Hilpert F, Mahner S, Baumann K, Schr\u00f6der W, Burges A, Canzler U, Chien J, Embleton AC, Parmar M, Kaplan R, Perren T, Hartmann LC, Goode EL, Dowdy SC and Pfisterer J<\/p>\n

Clin Cancer Res 2017 Jul 15;23(14):3794-3801[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 12<\/h3>\n

AGO-OVAR 12: A Randomised Placebo-Controlled GCIG\/ENGOT-Intergroup Phase III Trial of Standard Frontline Chemotherapy +\/- Nintedanib for Advanced Ovarian Cancer<\/p>\n

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidzinski M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Sambia G, Meier W, Nicoletto MO, Bj\u00f8rge L, Lortholary A, Sailer MO, Merger M, Harter P, on behalf of the AGO Study Group led Gynecologic Cancer Intergroup (GCIG) \/ European Network of Gynaecologic Oncology Trials Group (ENGOT) Intergroup Consortium<\/p>\n

The Lancet Oncology, Vol 17, No. 1, p78\u201389, January 2016<\/p>\n

Published online November 15, 2015
DOI: http:\/\/dx.doi.org\/10.1016\/S1470-2045(15)00366-6<\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Nintedanib and ovarian cancer: standardise surgery in trials?<\/p>\n

Kehoe S<\/p>\n

Published online November 15, 2015: https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(15)00398-8\/fulltext<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 15<\/h3>\n

Randomized Phase II Trial of Carboplatin and Paclitaxel with or without Lonafarnib in First-Line Treatment of Epithelial Ovarian Cancer Stage IIB-IV<\/p>\n

Meier W, du Bois A, Rau J, Gropp M, Baumann KH, Huober J, Wollschlaeger K, Kreienberg R, Canzler U, Schmalfeldt B, Wimberger P, Richter B, Schr\u00f6der W, Belau A, St\u00e4hle A, Burges A, Sehouli J<\/p>\n

Gynecologic Oncology 126 (2012) 236\u2013240[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 16<\/h3>\n

Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer<\/p>\n

du Bois A, Floquet A, Kim J-W, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier M-A, Kim J-H, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim B-G, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Cressenzo R, Harter P<\/p>\n

J Clin Oncol. 2014 Oct 20; 32:3374-82, doi: 10.1200\/JCO.2014.55.7348, Epub 2014 Sep 15[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR 16 trial<\/p>\n

Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Ionishi S, Crescenzo R J, Barrett C, Wang K, Mitrica I, du Bois A<\/p>\n

Gynecologic Oncology 136 (2015) 37-42, DOI: https:\/\/www.gynecologiconcology-online.net\/article\/S0090-8258(14)01547-9\/fulltext<\/a><\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]BRCA1\/2 mutations associated with progression free survival in ovarian cancer patients in the AGO-OVAR 16 study<\/p>\n

Harter P, Johnson T, Berton-Rigaud D, Park SY, Friedlander M, del Campo JM, Shimada M, Forget F, Mirza MR, Colombo N, Zamagni C, Chan JK, Imhof M, Herzog TJ, O’Donnell D, Heitz F, King K, Stinnett S, Barrett C, Jobanputra M, XU CF, du Bois A<\/p>\n

Gynecol Oncol 2016 Mar; 140(3): 443-9. doi: 10.1016\/j.ygyno.2015.12.027. Epub 2015 Dec 29[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Communicating BRCA Research Results to Patients Enrolled in International Clinical Trials: Lessons Learnt From the AGO-OVAR 16 Study<\/p>\n

Pulford D, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox Ch, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A<\/p>\n

BMC Medical Ethics (2016) 17:63, DOI: 10.1186\/s12910-016-0144-y[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters – patient-centered end points in trials of maintenance therapy<\/p>\n

Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King MT, Debruyne P, Bologna A, Malander S, Monk BJ, Petru E, Calvert P, Herzog TJ, Barrett C, du Bois A<\/p>\n

Annals of Oncology 29: 737-743, 2018<\/p>\n

doi:10.1093\/annonc\/mdx796<\/p>\n

Published online 18 December 2017[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.19.5″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 17 \/ BOOST<\/h3>\n

Optimal Treatment Duration of Bevacizumab as First-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST\/GINECO OV118\/ENGOT Ov-15 Open-Label Randomized Phase III Trial<\/p>\n

Pfisterer J, Joly F, Kristensen GB, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, Sehouli J, Heubner M, Hartkopf A, Bauman K, Hasenburg A, Hanker L, Belau A, Schmalfeldt B, Denschlag D, Park-Simon TW, Selle F, Jackisch W, de Gregorio N, Hilpert F, Harter P<\/p>\n

Journal of Clinical Oncology 2023 41:4, 893-902.
<\/strong>DOI: 10.1200\/JCO.22.01010
Published online November 04, 2022.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 18 \/ TRINOVA 3<\/h3>\n

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): a randomised, double-blind, phase 3 trial<\/p>\n

Vergote I, Scambia G, O\u2019Malley DM, van Calster B, Park SY, del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Mirza MR, Kroep JR, Ma H, Pickett CA, Monk BJ<\/p>\n

Lancet of Oncology; online first; Published May 7, 2019
https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(19)30178-0\/fulltext<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 20 \/ PAOLA-1<\/h3>\n

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer<\/p>\n

Ray Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez Mart\u00edn A, Berger R, Fujiwara K, Vergote I, ColomboN, M\u00e4enp\u00e4\u00e4 J, Selle F, Sehouli J, Lorusso D, Guerra Al\u00eda E M, Reinthaller A, Nagao S, Lefeuvre Plesse C, Canzler U, Scambia G, Lortholary A, Marm\u00e9 F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade Lauraine E, and Harter P for the PAOLA-1 Investigators<\/p>\n

N Engl J Med 2019;381:2416-28.
DOI: 10.1056\/NEJMoa1911361<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

<\/h3>\n

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial<\/p>\n

Harter P, Mouret-Reynier MA, Pignata S, Cropet C, Gonz\u00e1lez-Martin A, Bogner G, Fujiwara K, Vergote I, Colombo N, Jakobi N\u00f8ttrup T, Floquet A, El-Balat A, Scambia G, Guerra-Alia EM, Fabbro M, Schmalfeldt B, Hardy-Bessard AC, Runnebaum I, Pujade-Lauraine E, Ray-Coquard I<\/p>\n

Gynecologic Oncology 164 (2022) 254-264<\/p>\n

Published online: Dec 22, 2021
https:\/\/doi.org\/10.1016\/j.ygyno.2021.12.016<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.20.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

<\/h3>\n

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: Phase III PAOLA-1\/ENGOT-ov25 trial subgroup exploratory analysis<\/p>\n

Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, N\u00f8ttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martin-Lorente C, Pujade-Lauraine E, Fi\u00e9vet A, Ray-Coquard IL<\/p>\n

Annals of Oncology,
Volume 34, Issue 2,2023,pp:152-162
online 28 November 2022
https:\/\/doi.org\/10.1016\/j.annonc.2022.11.003\u00a0<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.21.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

<\/h3>\n

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial<\/p>\n

Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonz\u00e1lez-Martin A, Marth C, Nagao S, Vergote I, Colombo N, M\u00e4enp\u00e4aa J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P<\/p>\n

Annals of Oncology – Volume 34, Issue 8, P681-692, August 2023
Published online: May 19, 2023
DOI:https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005\u00a0<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

<\/h3>\n

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1\/ENGOT-ov25 trial<\/p>\n

Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Al\u00eda, EM, Matsumoto T, Vergote I, Colombo N, M\u00e4enp\u00e4\u00e4 J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-P\u00e9rez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Ray-Coquard I<\/p>\n

Annals of Oncology, 2024, Vol 36, Issue 2, 185 – 196
https:\/\/www.annalsofoncology.org\/article\/S0923-7534(24)04907-X\/fulltext<\/a><\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

<\/h3>\n

Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides<\/p>\n

Frederik Marm\u00e9, Eva I. Krieghoff-Henning, Lennard Kiehl, Christoph Wies, Jan Hauke, Eric Hahnen, Philipp Harter, Philip C. Schouten, Tobias Brodkorb, Mohamad Kayali, Florian Heitz, Claudio Zamagni, Antonio Gonz\u00e1lez-Martin,Isabelle Treilleux, Stefan Kommoss, Katharina Prieske, Timo Gaiser, Stefan Fr\u00f6hling, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Titus J. Brinker<\/p>\n

European Journal of Cancer 216 (2025) 115199 \u00a0 https:\/\/doi.org\/10.1016\/j.ejca.2024.115199<\/a><\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.20.2″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 21 \/ PRIMA<\/h3>\n

Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial.<\/p>\n

Mirza MR, Gonz\u00e1lez-Mart\u00edn A, Graybill WS, O\u2019Malley D, Gaba L, Yap OWS, Guerra EM, Rose PG, Burain JF, Ghamande SA, Denys H, Prendergast E, Pisano C, Follana P, Baumann K, Calvert PM, Korach J, Li Y, Malinowska IA, Gupta D, Monk BJ<\/p>\n

Cancer. 2023; 1- 10. doi:10.1002\/cncr.34706<\/p>\n

 <\/p>\n

Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer<\/p>\n

Gonzalez Martin, A.J, Pothur B, Vergote IB, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O\u2019Cearbhaill RE, Malinowska I, Shtessel L, Compton N, Mirza MR, Monk BJ<\/p>\n

European Journal of Cancer 189 (2023) 112908
DOI: https:\/\/doi.org\/10.1016\/j.ejca.2023.04.024 Published online: May 02, 2023<\/p>\n

 <\/p>\n

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA\/ENGOT-OV26\/GOG-3012 trial<\/p>\n

Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill WS, Mirza MR, McCormick C, LorussoD, Moore rG, Freyer G, O\u2019Cearbhaill RE, Heitz F, O`Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Rubio P\u00e9rez MJ, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, Gonz\u00e1lez-Martin A<\/p>\n

Annals of Oncology, 2024, Vol 35, Issue 11, 981 – 992
https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2241<\/a><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”][\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 22 \/ IMagyn050<\/h3>\n

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)<\/p>\n

Kathleen N. Moore, MD; Michael Bookman, MD; Jalid Sehouli, MD; Austin Miller, PhD; Charles Anderson, MD; Giovanni Scambia, MD; Tashanna Myers, MD; Cagatay Taskiran, MD; Katina Robison, MD; Johanna M\u00e4enp\u00e4\u00e4, MD; Lyndsay Willmott, MD; Nicoletta Colombo, MD; Jessica Thomes-Pepin, MD; Michalis Liontos, MD; Michael A. Gold, MD; Yolanda Garcia, MD; Sudarshan K. Sharma, MD; Christopher J. Darus, MD; Carol Aghajanian, MD; Aikou Okamoto, MD; Xiaohua Wu, MD; Rustem Safin, MD; Fan Wu, MS; Luciana Molinero, MD; Vidya Maiya, MD; Victor K. Khor, PhD; Yvonne G. Lin, MD; and Sandro Pignata, MD<\/p>\n

Journal of Clinical Oncology; Published at ascopubs.org\/journal\/jco on April 23, 2021:
DOI https:\/\/doi.org\/10.1200\/JCO.21.00306<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.6″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 23 \/ DUO-O<\/h3>\n

Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer<\/p>\n

Harter P, Trillsch F, Okamoto A, Reuss A, Kim JW, Rubio Perez MJ, Vardar MA, Scambia G, Tred\u00e1n O, Nyvang G, Colombo N, Bidzi\u0144ski M, Grimm C, Lheureux S, van Nieuwenhuysen E, Heitz F, Wenham R, Nishio S, Lim MC, Marquin G, Ayhan A, Bergamini A, Sabatier R, Wimberger P, Gold M, Sehouli J, Park-Simon TW, Kent E, Correa A and Aghajanian C, on behalf of the DUO-O Investigators<\/p>\n

Annals of Oncology, 2025; 37, 503-520
https:\/\/www.annalsofoncology.org\/article\/S0923-7534(25)06315-X\/fulltext<\/a><\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 24 \/ FIRST<\/h3>\n

Dostarlimab and niraparib in primary advanced ovarian cancer<\/p>\n

Hardy-Bessard AC, Pujade-Lauraine, Moore RG, Montestruc F, Redondo A, Mirza MR, Cibual D, Ciuleanu TE, Gilbert L, Eitan R, Zagouri F, Pignata S, Glasspool R, Pfisterer J, Phaeton R, Anderson CK, Rodrigues M, Gaba L, Bakirtzi E, Fauci JM, Kalbacher E, Musa FB, Gorman S, Duska LR, Gladieff L Braly P, Joly F, Thomes Pepin J, Ray-Coquard I, Moore, KN<\/p>\n

Annals of Oncology 2025<\/p>\n

Dostarlimab and niraparib in primary advanced ovarian cancer – Annals of Oncology<\/strong><\/a><\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.19.1″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 25 \/ ATHENA<\/h3>\n

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA\u2013MONO\/GOG-3020\/ENGOT-ov45)<\/p>\n

Monk BJ, Parkinson C, Lim MC, O\u2019Malley DM, Oaknin A, Wilson MK, Colemann RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Droch\u00fdtej V, Barlin JN, van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Morre K, Marm\u00e9 F, Westin SN McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS<\/p>\n

Journal of Clinical Oncology 40, no. 34 (December 01, 2022) 3952-3964
Published online June 06, 2022
DOI: 10.1200\/JCO.22.01003<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”rezidiv” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Relapse therapy<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.1<\/h3>\n

Chemotherapy versus Hormonal Treatment in Platinum- and Paclitaxel-Refractory Ovarian Cancer: A Randomized Trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer<\/p>\n

A du Bois, W Meier, HJ L\u00fcck, G Emons, V M\u00f6bus, W Schr\u00f6der, S Costa, T Bauknecht, S Olbricht, C Jackisch, B Richter, U Wagner<\/p>\n

Annals of Oncology 13:251-257,2002[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.2<\/h3>\n

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR 2.2 trial<\/p>\n

The ICON and AGO Collaborators (writing committee)<\/p>\n

Lancet 361: 2099-2106 (2003)[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.3<\/h3>\n

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum\/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)<\/p>\n

W Meier, A du Bois, A Reuss, W Kuhn, S Olbricht, M Gropp, B Richter, HJ L\u00fcck, R Kimmig, J Pfisterer<\/p>\n

Gynecologic Oncology 114 (2009) 199-205[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.4<\/h3>\n

2nd-line chemotherapy with carboplatin and gemcitabine in patients with platinum sensitive recurrent ovarian cancer. A phase I\/II study of the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) Ovarian Cancer Study Group<\/p>\n

A du Bois, HJ L\u00fcck, J Pfisterer, W Schroeder, JU Blohmer, R Kimmig, V Moebus, J Quaas<\/p>\n

Annals of Oncology 12: 1115-1120, 2001
\nW Meier, A du Bois, A Reuss, W Kuhn, S Olbricht, M Gropp, B Richter, HJ L\u00fcck, R Kimmig, J Pfisterer<\/p>\n

Gynecologic Oncology 114 (2009) 199-205[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.5<\/h3>\n

Gemcitabine plus carboplatin versus carboplatin in patients with platinum-sensitive-recurrent ovarian cancer<\/p>\n

Pfisterer J, Plante M, Vergote I, Zimmerman A, du Bois A, Hirte H, Lacave A J, Wagner U, St\u00e4hle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, L\u00fcck H-J, Rochon J, Zimmermann A H, Eisenhauer E for the AGO OVAR, NCIC CTG and EORTC GCGPfisterer J, Plante M, Vergote I, Zimmerman A, du Bois A, Hirte H, Lacave A J, Wagner U, St\u00e4hle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, L\u00fcck H-J, Rochon J, Zimmermann A H, Eisenhauer E for the AGO OVAR, NCIC CTG and EORTC GCG<\/p>\n

J Clin Oncol 24:4699-4707, 2006[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.6<\/h3>\n

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy \u2013 A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)<\/p>\n

Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, L\u00fcck HJ, Sehouli J, Gropp M, St\u00e4hle A, Schmalfeldt, B, Meier W, Jackisch C<\/p>\n

Gynecol Oncol 2007; 105:132-137[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.8<\/h3>\n

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer – A phase I trial of the AGO-OVAR<\/p>\n

Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reu\u00df A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert , On behalf of the AGO-OVAR<\/p>\n

Ann Oncol 17: 1568-1577, 2006[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.9<\/h3>\n

Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel an carboplatin for patients with platinum-sensitive ovarian cancer in late relapse<\/p>\n

Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey P A, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, and du Bois A<\/p>\n

J Clin Oncol 28:3323-3329, 2010[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.9<\/h3>\n

Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel an carboplatin for patients with platinum-sensitive ovarian cancer in late relapse<\/p>\n

Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey P A, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, and du Bois A<\/p>\n

J Clin Oncol 28:3323-3329, 2010[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial<\/p>\n

Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell\u2019Anna T, Cretin J, Havsteen H, Besette P, Zeimet AG, Vergote I, Vasey P, Pujade-Lauraine E, Gladieff L, Ferrero AM<\/p>\n

European Journal of Cancer (2015) 51, 352-358[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.10<\/h3>\n

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group<\/p>\n

Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, Vergote I, L\u00fcck HJ, Wagner U<\/p>\n

Gynecol Oncol 2011; 123:27-32[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.11<\/h3>\n

A Phase II Trial (AGO 2.11) in platinum resistant Ovarian Cancer: a randomized multicenter trial with Sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy<\/p>\n

Baumann K, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U<\/p>\n

Annals of Oncology 23:2265-2271, 2012[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.12<\/h3>\n

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)<\/p>\n

Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W<\/p>\n

Ann Oncol. (2016) 27 (12):2236-2241[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.13<\/h3>\n

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I\/II study of the AGO Study Group (AGO-OVAR 2.13)<\/p>\n

Philipp Harter, Jalid Sehouli, Rainer Kimmig, J\u00f6rn Rau, Felix Hilpert, Christian Kurzeder, Gabriele Elser, Andreas du Bois<\/p>\n

Invest New Drugs (2013) 31:1499-1504[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.15<\/h3>\n

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial<\/p>\n

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I on behalf of the ENGOT-GCIG investigators<\/p>\n

J Clin Oncol 32:1302-1308, 2014; DOI:10.1200\/JCO.2013.51.4489[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.15<\/h3>\n

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial<\/p>\n

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I on behalf of the ENGOT-GCIG investigators<\/p>\n

J Clin Oncol 32:1302-1308, 2014; DOI:10.1200\/JCO.2013.51.4489[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Patient reported outcome resuluts from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer<\/p>\n

Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee C, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E<\/p>\n

J Clin Oncol 43:1309-1316,2014; DOI: 10.1200\/JCO.2013.51.4240[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Editorial Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer<\/p>\n

Joyce F. Liu and Stephen A. Cannistra<\/p>\n

J Clin Oncol 2014, Mar 17 [Epub ahead of print]; DOI:10.1200\/JCO.2013.54.7299[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Bevacizumab combined with weekly Paclitaxel, Pegylated Liposomal Doxurubicin, or Topotecan in platinum-resistend recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized Phase III AURELIA trial<\/p>\n

Poveda A, Selle F, Hilpert F, Reu\u00df A, Savarese A, Vergote I, Witteveen P, Bamias A, Scotto N, Mitchell L, Pujade-Lauraine E<\/p>\n

J Clin Oncol 2015 33(32):3836-8<\/p>\n

doi: 10.1200\/JCO.2015.63.1408.Epub 2015 Aug 17
https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2015.63.1408<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.16 \/ MITO 8<\/h3>\n

Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer<\/p>\n

Pignata S, Scambia G, Bologna A, Signoriello S, Vergote I, Wagner U, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce JC, Gennaro D, Piccirillo MC, Gallo C, Perrone F<\/p>\n

J Clin Oncol. 2017 Oct 10;35(29):3347-3353.<\/p>\n

doi: 10.1200\/JCO.2017.73.4293. Epub 2017 Aug 21[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.17<\/h3>\n

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial<\/p>\n

Amit M Oza, David Cibula, Ana Oaknin Benzaquen, Christopher Poole, Ron HJ Mathijssen, Gabe S Sonke, Nicoletta Colombo, Jiri Spacek, Peter Vuylsteke, Holger Hirte, Sven Mahner, Marie Plante, Barbara Schmalfeldt, Helen Mackay, Jacqui Rowbottom, Elisabeth S Lowe, Brian Dougherty, J Carl Barrett, Michael Friedlander<\/p>\n

The Lancet Oncology, Volume 16, Issue 1, 87 – 97
https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(14)71135-0\/fulltext<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.18\/TRIAS<\/h3>\n

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial<\/p>\n

Chekerov R, Hilpert F, Mahner S, El-Balat A, Harter P, de Gregorio N, Fridrich C, Markmann S, Potenberg P, Lorenz R, Oskay-Oezcelik G, Schmidt M, Krabisch P, Lueck HJ, Richter R, Braicu EI, du Bois A, Sehouli J<\/p>\n

The Lancet Oncology, DOI: https:\/\/doi.org\/10.1016\/S1470-2045(18)30372[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.19\/TRINOVA-2<\/h3>\n

ENGOT-ov-6\/TRINOVA-2: Randomized, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer<\/p>\n

Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Sevilay A, Rustin G, Wenham RM, Mirza M, Fong PC, Oza A, Monk BJ, Ma H, Vogl FK, Bach BA<\/p>\n

European Journal of Cancer 70 (2017) 111-121
https:\/\/www.ejcancer.com\/article\/S0959-8049(16)32425-X\/fulltext<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.20<\/h3>\n

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)<\/p>\n

Kurzeder C, Bover I, Marm\u00e9 F, Rau J, Pautier P, Colombo N, Lorusso D, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, del Campo JM, Mahner S, Bastiere-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A and Gonzalez-Martin A<\/p>\n

J Clin Oncol. 2016 Jul 20;34(21):2516-25. doi:10.1200\/JCO.2015.66.0787. Epub 2016 Jun 6[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial<\/p>\n

Gonz\u00e1lez-Mart\u00edn A, Pautier P, Mahner S, Rau J, Colombo N, Ottevanger P, del Campo JM, Selle F, du Bois A, Gadducci A, Garcia Y, Berton-Rigaud D, Marm\u00e9 F, Ortega E, Martin N, Bastiere-Truchot L, Kiermaier A, Kurzeder C<\/p>\n

Int J Gynecol Cancer. 2016 Jun;26(5):898-905. doi: 10.1097\/IGC.0000000000000695[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.21<\/h3>\n

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial<\/p>\n

Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau, Philipp Harter, Florence Joly, Jalid Sehouli, Ulrich Canzler, Barbara Schmalfeldt, Andrew P Dean, Alexander Hein, Alain G Zeimet, Lars C Hanker, Thierry Petit, Frederik Marm\u00e9, Ahmed El-Balat, Rosalind Glasspool, Nikolaus de Gregorio, Sven Mahner, Tarek M Meniawy, Tjoung-Won Park-Simon, Marie-Ange Mouret-Reynier, Cristina Costan, Werner Meier, Alexander Reinthaller, Jeffrey C Goh, Tifenn L\u2019Haridon, Sally Baron Hay, Stefan Kommoss, Andreas du Bois, Jean-Emmanuel Kurtz, for the AGO-OVAR 2.21\/ENGOT-ov 18 Investigators<\/p>\n

Lancet Oncol 2020<\/p>\n

Published Online April 16, 2020 https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(20)30142-X\/fulltext<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.22\/NOVA<\/h3>\n

Niraparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer<\/p>\n

Mirza MR, Monk B, Herrstedt J, Oza A, Mahner S, Redondo A, Fabbro M, Ledermann J, Lorusso K, Vergote I, Ben-Baruch EN, Marth C, Madry R, Christensen.., Berek J, D\u00f8rum A, Tinker A, du Bois A, Gonzalez M, Fallana P, Benigno B, Rosenberg P, Gilbert L, Rimel B, Buscema J, Balser J, Agarwal S, Matulonis U<\/p>\n

N Engl J Med 2016; Published online 8. Oktober 2016<\/p>\n

DOI 10.1056\/NEJMoa1611310[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.23\/SOLO 2<\/h3>\n

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial<\/p>\n

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P, the SOLO2\/ENGOT-Ov21 investigators<\/p>\n

Published Online July 25, 2017 https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(17)30469-2\/fulltext<\/a><\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial<\/p>\n

Andr\u00e9s Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S Sonke, Alla Lisyanskaya, Jae-Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S Lowe, Phil Rowe, Ignace Vergote, Eric Pujade-Lauraine, the SOLO2\/ENGOT-Ov21 investigators<\/p>\n

Published online March 18, 2021 https:\/\/doi.org\/10.1016\/S1470-2045(21)00073-5<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Efficacy and safety of olaparib according to age in BRCA1\/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2\/ENGOT-Ov21 study<\/p>\n

Trillsch F, Mahner S, Ataseven B, Asher R, Aryal N, Dubot C, Clamp A, Penson RT, Oza A, Amit A, Huzarski T, Casado A, Scambia G, Friedlander M, Colombo N, Fujiwara K, Sonke GS, Denys H, Lowe ES, Lee CK, Pujade-Lauraine E<\/p>\n

Gynecol Oncol. 2022 Apr;165(1):40-48. doi: 10.1016\/j.ygyno.2022.01.024.
Epub 2022 Jan 31<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.17.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2\/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer<\/p>\n

Francis KE, Kim SI, Friedlander M, Gebski V, Ray-Coquard I, Clamp A, Penson RT, Oza A, Perri T, Huzarsk T, Martin-Lorente C, Cecere SC, Colombo N, Ataseven B, Fujiwara K, Sonke G, Pujade-Lauraine E, Kim JW, Lee CK<\/p>\n

Annals of Oncology, 2022, Volume 33, Issue 6, 593 \u2013 601
https:\/\/doi.org\/10.1016\/j.annonc.2022.02.222<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.25\/GANNET53<\/h3>\n

Part I of GANNET53: A European Multicenter Phase I\/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer \u2013 A Study of the GANNET53 Consortium<\/p>\n

Isabelle Ray-Coquard, Ioana Braicu, Regina Berger, Sven Mahner, Jalid Seouli, Eric Pujade-Lauraine, Philippe Alexandre Cassier, Ute Martha Moll, Hanno Ulmer, Karin Leunen, Alain Gustave Zeimet, Christian Marth, Ignace Vergote and Nicole Concin on behalf of the entire GANNET53 Consortium (18 Partner Institutions in Europe)<\/p>\n

Front. Oncol. 9:832. doi: 10.3389\/fonc.2019.00832<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.29<\/h3>\n

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29\/ENGOT-ov34 Phase III Trial<\/p>\n

Harter P, Marm\u00e9 F, Redondo A, Reuss A, Lindemann K, Kurzeder C, Van Nieuwenhuysen E, Marth C, Pietzner K, RayCoquard I, Garcia-Duran C, Jonuskiene G, Heitz F, B\u00e9llier C, P\u00e9rez-Fidalgo A, El Balat A, Selle F, Romero I, Wimberger P, Follana P, Pardo B, de Gregorio N, Joly F, Gaba L, Burges A, Fabbro M, Hasenburg A, Fehm T, Schmalfeldt B, Pautier P<\/p>\n

J Clin Oncol. 2026 Jan 10;44(2):103-116<\/p>\n

https:\/\/doi.org\/10.1200\/jco-25-01210<\/a><\/p>\n

 <\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.22.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.30\/ATALANTE<\/h3>\n

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE\/ENGOT-ov29 Trial<\/p>\n

Jean-Emmanuel Kurtz, MD, PhD; Eric Pujade-Lauraine, MD; Ana Oaknin, MD; Lisa Belin, MSc; Katharina Leitner, MD; David Cibula, MD; Hannelore Denys, MD; Ora Rosengarten, MD; Manuel Rodrigues, MD; Nikolaus de Gregorio, MD; Jeronimo Martinez Garc\u00eda, MD ; Edgar Petru, MD; Roman Koci\u00e1n, MD; Ignace Vergote, MD; Patricia Pautier, MD; Barbara Schmalfeldt, MD; Lydia Gaba, MD; Stephan Polterauer, MD; Marie-Ange Mouret Reynier, MD; Jalid Sehouli, MD; Cristina Churruca, MD; Fr\u00e9d\u00e9ric Selle, MD; Florence Joly, MD; V\u00e9ronique D\u2019Hondt, MD; \u00c9milie Bultot-Boissier, MD; Coriolan Lebreton, MD; Jean-Pierre Lotz, MD; R\u00e9my Largillier, MD29; Pierre-Etienne Heudel, MD; and Florian Heitz, MD; on behalf of the ATALANTE\/ENGOT-ov29 Investigators<\/p>\n

Journal of Clinical Oncology 2023 41:30, 4768-4778,\u00a0 Published August 29, 2023
<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.22.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.31\/OReO<\/h3>\n

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial<\/p>\n

Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marm\u00e9 F, Lindemann K, Colombo N, M\u0105dry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-P\u00e9rez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A, on behalf of the OReO\/ENGOT-ov38 investigators<\/p>\n

Annals of Oncology (2023), Published 3. October 2023
DOI:https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3110<\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.33\/ANITA<\/h3>\n

Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41\/GEICO 69-O\/ANITA Phase III Trial<\/p>\n

Gonzalez Martin A, Rubio MJ, Heitz F, dePont Christensen R, Colombo N, Van Gorp T, Romeo M, Ray-Coquard I, Gaba L, Leary A, De Sande LM, Lebreton C, Redondo A, Fabbro M, Barretina-Ginesta MP, Follana P, P\u00e9rez-Fidalgo A, Rodrigues M, Santaballa A, Sabatier R, Bermejo-P\u00e9rez MJ, Lotz JP, Pardo B, Marquina G, S\u00e1nchez-Lorenzo L, Quind\u00f3s M, Est\u00e9vez-Garci\u00e1 MJ, Guerra Alia E, Manso L, Casado V, Kommoss S, Tognon G, Henry S, Bruchim I, Oaknin A, Selle F<\/p>\n

J Clin Oncol 42. 4294-4304(2024).
DOI:10.1200\/JCO.24.00668<\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.38\/SORAYA<\/h3>\n

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study<\/p>\n

Matulonis U, Lorusso D, Oakinin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Romeo M, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL<\/p>\n

Journal of Clinical Oncology 2023 41:13, 2436-2445
DOI: 10.1200\/JCO.22.01900
Published online January 30, 2023.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”uterus” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Uterus<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-GYN 2<\/h3>\n

Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I\/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)<\/p>\n

A. du Bois, A. Burges, W. Meier, J. Pfisterer, B. Schmalfeldt, B. Richter, C. Jackisch, A. Staehle, R. Kimmig & G. Elser on behalf of AGO-OVAR Germany<\/p>\n

Annals of Oncology 17: 93-96, 2006<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-GYN 3<\/h3>\n

Combination Therapy with Pegylated Liposomal Doxorubicin and Carboplatin in Gynecologic Malignancies: A Prospective Phase-II Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut)<\/p>\n

du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Staehle A, Jackisch C, Koelbl H<\/p>\n

Gynecol Oncol 2007; 107: 518-525<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-GYN 4<\/h3>\n

A Phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies<\/p>\n

du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S Reichardt V, Harter P<\/p>\n

Annals of Oncol 2010 21:370-375<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-GYN 5<\/h3>\n

Efficiacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors, A Multicenter Phase 2 Trial (AGO-GYN 5)<\/p>\n

G\u00fcnter Emons, Grigor Gorchev, Philipp Harter, Pauline Wimberger, Anne St\u00e4hle, Lars Hanker, Felix Hilpert, Matthias W. Beckmann, Peter Dall, Carsten Gr\u00fcndker, Herbert Sindermann, Jalid Sehouli<\/p>\n

Int J Gynecol Cancer 2014; 24, Number 2: 260-265<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)<\/p>\n

G\u00fcnter Emons, Grigor Gorchev, Jalid Sehouli, Pauline Wimberger, Anne St\u00e4hle, Lars Hanker, Felix Hilpert, Herbert Sindermann, Carsten Gr\u00fcndker, Philipp Harter<\/p>\n

Gynecol Oncol 133 (2014): 427-432[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-GYN 6<\/h3>\n

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I\/II trial of the AGO study group
du Bois A, Vergote I, Wimberger P, Ray-Coquard I, Harter P, Baylor Curtis L, Mitrica I<\/p>\n

British Journal of Cancer 2012; 106, 629-632<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-GYN 7<\/h3>\n

Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors<\/p>\n

A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7)<\/p>\n

Philipp Harter, Jalid Sehouli, Alexander Reuss, Klaus Baumann, Lars Hanker, Rainer Kimmig, Willibald Schr\u00f6der, Alexander Burges, Martina Gropp-Meier, Christian Kurzeder, Sven Mahner, Ulrich Canzler, Hans-Joachim L\u00fcck, Werner Meier, Tanja Fehm, and Andreas du Bois<\/p>\n

Int J Gynecol Cancer. 2016 Nov; 26(9):1636-1641. DOI:10.1097\/IGC.0000000000000831. Epub 2016 Sep 19<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-GYN 8<\/h3>\n

Temsirolismus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN 8)<\/p>\n

Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schr\u00f6der W, L\u00fcck HJ, Heubner ML, Hanker L, Thiel F, Hilpert F<\/p>\n

Gynecol Oncol. 140 (2016) 450-456<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-GYN 9 \/ ALIENOR<\/h3>\n

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal TumorsThe ALIENOR\/ENGOT-ov7 Randomized Clinical Trial<\/span><\/p>\n

Isabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, C\u00e9cile Dalban, Ignace Vergote, Keiichi Fujiwara, Laurence Gladieff, Hans-Joachim L\u00fcck, Anne Floquet, Annick Chevalier-Place, Andreas Schnelzer, Sandro Pignata, Fr\u00e9d\u00e9ric Selle, Jalid Sehouli, Fabien Brocard, Giorgia Mangili, Patricia Pautier, Ugo De Giorgi, Magali Provansal, Pierre-Etienne Heudel<\/p>\n

JAMA Oncol. <\/span> 2020;6(12):1923-1930. doi:10.1001\/jamaoncol.2020.4574<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.27.0″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-EN 2 \/ AtTEnd<\/h3>\n

Atezolizumab and chemotherapy for advanced or recurrent\u00a0 endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial<\/p>\n

Colombo N, Biagioli E, Harana K, Galli F, Huson E, Antill Y, Choi CH, Rabaglio M, Marm\u00e9 F, Marth C, Parma G, Farinas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesata MP, and AtTEnd study group<\/p>\n

Lancet Oncol 2024 , Published Online August 2, 2024<\/p>\n

https:\/\/doi.org\/10.1016\/S1470-2045(24)00334-6<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.27.0″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-EN 3 \/ RUBY<\/h3>\n

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer<\/p>\n

M.R. Mirza, D.M. Chase, B.M. Slomovitz, R. dePont Christensen, Z. Nov\u00e1k, D. Black, L. Gilbert,
S. Sharma, G. Valabrega, L.M. Landrum, L.C. Hanker, A. Stuckey, I. Boere, M.A. Gold,
A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M.S. Shahin, S.E. Gill, B.J. Monk,
J. Buscema, T.J. Herzog, L.J. Copeland, M. Tian, Z. He, S. Stevens, E. Zografos, R.L. Coleman,
and M.A. Powell, for the RUBY Investigators<\/p>\n

The New England Journal of Medicine, March 27, 2023, NEJM.org.
DOI: 10.1056\/NEJMoa2216334<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.27.0″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-EN 4<\/h3>\n

ENGOT-en11\/GOG-3053\/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer<\/p>\n

Van Gorp T, Cibula D, Lu W, Backes F, Ortac F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Berr\u00edos Flores MP, Levy T, Colombo N, Padamitriou C, Buchanan T, Hanker L, Emonwicz G, Rob L, Black D, Lichfield J, Lin G, Orlowski R, Keefe S, Lortholary A, Slomowitz B, on behalf of the ENGOT-en11\/GOG-3053\/KEYNOTE-B21 investigators<\/p>\n

Annals of Oncology, 2024, Volume 35, Issue 11, 968 \u2013 980
https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2242<\/a><\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”vulva” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Vulva<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-CaRE 1<\/h3>\n

Adjuvant Therapy in Lymph Node\u2013Positive Vulvar Cancer: The AGO-CaRE-1 Study<\/p>\n

Sven Mahner, Julia Jueckstock, Felix Hilpert, Petra Neuser, Philipp Harter, Nikolaus de Gregorio, Annette Hasenburg, Jalid Sehouli, Annika Habermann, Peter Hillemanns, Sophie Fuerst, Hans-Georg Strauss, Klaus Baumann, Falk Thiel, Alexander Mustea, Werner Meier, Andreas du Bois, Lis-Femke Griebel, Linn Woelber; for the AGO-CaRE 1 investigators<\/p>\n

JNCI J Natl Cancer Inst (2015) 107(3):dju426 [\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer<\/p>\n

Eulenburg C, Suling A, Neuser B, Reuss A, Canzler U, Fehm T, Luyten A, Hellriegel M, Woelber L, Mahner S<\/p>\n

PLoS ONE 11(11): e0165705.doi: 10.1371\/journal.pone.0165705[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Role of tumor-free margin distance for loco-regional control in vulvar cancer – a subset analysis of the AGO CaRE-1 multicenter study<\/p>\n

W\u00f6lber L, Griebel LF, Eulenburg C, Sehouli J, J\u00fcckstock J, Hilpert F, de Gregorio N, Hasenburg A, Ignatov A, Hillemanns P, F\u00fcrst S, Strauss HG, Baumann KH, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker LC, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Neuser P, Mahner S<\/p>\n

European Journal of Cancer 69 (2016):180 – 188<\/p>\n

https:\/\/www.ejcancer.com\/article\/S0959-8049(16)32484-4\/fulltext<\/a><\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Outcome after Sentinel lymph node dissection in vulvar cancer. A subgroup analysis of the AGO-CaRE-1-study<\/p>\n

Klapdor R, Hillemanns P, J\u00fcckstock J, W\u00f6lber L, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Habermann A, F\u00fcrst ST, Strau\u00df HG, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, J\u00e4ger M, Mahner S<\/p>\n

Ann Surg Oncol (2017) 24:1314[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study<\/p>\n

Plterauer S, Schwameis R, Grimm C, Hillemanns P, J\u00fcckstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, F\u00fcrst ST, Strau\u00df HG, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, K\u00f6lbl H, Reinthaller A, Woelber L, Mahner S<\/p>\n

Gynecol Oncol 153 (2019) pp 286-291[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-VOP.2 \/ QS Vulva<\/h3>\n

Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 \/ QS Vulva<\/p>\n

Woelber L, Hampl M, Eulenburg CZ, Prieske K, Hambrecht J, Fuerst S, Klapdor R, Heublein S, Gass P, Rohner A, Canzler U, Becker S, Bommert M, Bauerschlag D, Denecke A, Hanker L, Runnebaumn I, Forner DM, Schochter F, Klar M, Schwab R, Koepke M, Kalder M, Hantschmann P, Ratiu D, Denschlag D, Schroeder W, Tuschy B, Baumann K, Mustea A, Soergel P, Bronger H, Bauerschmitz G, Kosse J, Koch MC, Ignatov A, Sehouli J, Dannecker C, Mahner S, Jaeger A<\/p>\n

Cancers (Basel). 2022 Jan 14;14(2):418
doi: 10.3390\/cancers14020418\u00a0<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study<\/p>\n

Jaeger A, Hampl, M, Prieske K, Eulenburg C, Reichenbach J, Klapdor R, Heublein S, Schochter F, Ga\u00df P, Rohner A, Canzler U, Becker S, Bommert M, Bauerschlag D, DenekeA, Hanker L, Runnebaum I, Forner DM, Klar M, Schwab R, Koepke M, Kalder M, Hantschmann P, Ratiu D, Denschlag D, Schroeder W, Tuschy B, Baumann K, Mustea A, Soergel P, Bronger H, Bauerschmitz G, Kosse J, Koch MC, Ignatov A, Sehouli J, Dannecker C, Schmalfeldt B, Mahner S, Woelber L.<\/p>\n

Gynecologic Oncology, 2025, Vol 200, p:8 \u2013 13
https:\/\/doi.org\/10.1016\/j.ygyno.2025.07.003<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”cervix” _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.23.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.23.1″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Cervix\u00a0<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.23.1″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-ZX 3 \/ BEATcc<\/h3>\n

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial<\/p>\n

Oaknin A, Gladieff L, Mart\u00ednez-Garc\u00eda J, Villacampa G, Takekuma M, de Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, J\u00e9sus Rubio M, Fari\u00f1as-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarc\u00f3n J, Follana P, Romero I, Lebreton C, P\u00e9rez-Fidalgo A, Yunokawa M, Dahlstrand H, D\u2019Hondt V, Randall L for the ENGOT-Cx10\/GEICO 68-C\/JGOG1084\/GOG-3030 Investigators<\/p>\n

The Lancet, Published online December 1, 2023 https:\/\/doi.org\/10.1016\/S0140-6736(23)02405-4\u00a0<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.23.1″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-ZX 4<\/h3>\n

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.<\/p>\n

Vergote I, Gonz\u00e1lez-Mart\u00edn A, Fujiwara K, Kalbacher E, Bagam\u00e9ri A, Ghamande S, Lee JY, Banerjee S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen E, Manso L, Woelber L, Westermann A, Covens A, Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz FM, Angelergues A, Cibula D, Barraclough L, Oaknin A, Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I, Slomovitz BM; innovaTV 301\/ENGOT-cx12\/GOG-3057 Collaborators<\/p>\n

N Engl J Med. 2024 Jul 4;391(1):44-55.<\/p>\n

doi: 10.1056\/NEJMoa2313811.\u00a0<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”op-frage” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Surgical issues<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.24.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OP.1 \/ DESKTOP I<\/h3>\n

Surgery in recurrent ovarian cancer – The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial<\/p>\n

Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schr\u00f6der W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J. Heilmann V for the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee (AGO OC) and the AGO Ovarian Cancer Study Group (AGO-OVAR)<\/p>\n

Ann Surg Oncol 2006 online first 10-2006<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.24.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OP.2 \/ DESKTOP II<\/h3>\n

Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer
The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO<\/p>\n

Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, P\u00f6lcher M, Kurzeder C, Canzler U, Petry K U, Obermair A, Petru E, Schmalfeldt B, Lorusso D, and du Bois A<\/p>\n

Int J Gynecol Cancer 2011, 21: 289-295<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OP.3 \/ LION<\/h3>\n

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms<\/p>\n

P. Harter, J. Sehouli, D. Lorusso, A. Reuss, I. Vergote, C. Marth, J.-W. Kim, F. Raspagliesi, B. Lampe, G. Aletti, W. Meier, D. Cibula, A. Mustea, S. Mahner, I.B. Runnebaum, B. Schmalfeldt, A. Burges, R. Kimmig, G. Scambia, S. Greggi, F. Hilpert, A. Hasenburg, P. Hillemanns, G. Giorda, I. von Leffern, C. Schade-Brittinger, U. Wagner, and A. du Bois<\/p>\n

N Engl J Med 2019;380:822-32<\/p>\n

 <\/p>\n

Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: An AGO-OVAR.OP3\/LION Exploratory analysis\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

\u00a0Trillsch F, Czogalla B, Mahner S, Loidl V, Reuss A, du Bois A, Sehouli J, Raspagliesi F, Meier W, Cibula D, Mustea A, Runnebaum I, Schmalfeldt B, Aletti G, Kimmig R, Scambia G, Hilpert F, Hasenburg A, Wagner U, Harter P<\/p>\n

Int J Surg. 2025 Apr 1;111(4):2914-2922. doi: 10.1097\/JS9.0000000000002306<\/a><\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.24.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OP.4 \/ DESKTOP III<\/h3>\n

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer<\/p>\n

P. Harter, J. Sehouli, I. Vergote, G. Ferron, A. Reuss, W. Meier, S. Greggi, B.J. Mosgaard, F. Selle, F. Guyon, C. Pomel, F. L\u00e9curu, R. Zang, E. Avall\u2011Lundqvist, J.-W. Kim, J. Ponce, F. Raspagliesi, G. Kristensen, J.-M. Classe, . Hillemanns, P. Jensen, A. Hasenburg, S. Ghaem\u2011Maghami, M.R. Mirza, B. Lund, A. Reinthaller, A. Santaballa, A. Olaitan, F. Hilpert, and A. du Bois, for the DESKTOP III Investigators<\/p>\n

N Engl J Med 2021;385:2123-31<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.24.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OP.5 \/ ROBOT<\/h3>\n

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): A subanalysis of the AGO ROBOT study<\/p>\n

F Trillsch, S Mahner, E Vettorazzi, L Woelber, A Reuss, K Baumann, M-D Keyver-Paik, U Canzler, K Wollschlaeger, D Forner, J Pfisterer, W Schroeder, K Muenstedt, B Richter, C Fotopoulou, B Schmalfeldt, A Burges, N Ewald-Riegler, N de Gregorio, F Hilpert, T Fehm, W Meier, P Hillemanns, L Hanker, A Hasenburg, H-G Strauss, M Hellriegel, P Wimberger, S Kommoss, F Kommoss, S Hauptmann and A du Bois<\/p>\n

British Journal of Cancer (2015), 1-7 doi: 10.1038\/bjc.2014.648, Advance Online Publication: 6 January 2015<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Corrigendum to “Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie AGO Study Group” Eur J Cancer 49 (2013) 1905-1914<\/p>\n

A du Bois, N Ewald-Riegler, N de Gregorio, A Reuss, S Mahner, C Fotopoulou, F Kommoss, B Schmalfeldt, F Hilpert T Fehm, A Burges, W Meier, P Hillemanns, L Hanker, A Hasenburg, H-G Strauss, M Hellriegel, P Wimberger, M-D Keyver-Paik, K Baumann, U Canzler, K Wollschlaeger, D Forner, J Pfisterer, W Schr\u00f6der, K M\u00fcnstedt, B Richter, S Kommoss, S Hauptmann<\/p>\n

Eur J Cancer 65 (2016) 192-193<\/p>\n

https:\/\/www.ejcancer.com\/article\/S0959-8049(16)32278-X\/fulltext<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OP.8 \/ SHAPE<\/h3>\n

Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer<\/p>\n

Marie Plante, M.D., Janice S. Kwon, M.D., Sarah Ferguson, M.D., Vanessa Samou\u00eblian, M.D., Gwenael Ferron, M.D., Amandine Maulard, M.D., Cor de Kroon, M.D., Willemien Van Driel, M.D., John Tidy, M.D., Karin Williamson, M.D., Sven Mahner, M.D., Stefan Kommoss, M.D., Frederic Goffin, M.D., Karl Tamussino, M.D., Brynhildur Eyj\u00f3lfsd\u00f3ttir, M.D., Jae-Weon Kim, M.D., Noreen Gleeson, M.D., Lori Brotto, Ph.D., Dongsheng Tu, Ph.D., and Lois E. Shepherd, M. for the CX.5 SHAPE investigators<\/p>\n

N Engl J Med 2024;390:819-29.
DOI: 10.1056\/NEJMoa2308900
https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2308900<\/a><\/p>\n

 <\/p>\n

Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG\/CCTG CX.5\/SHAPE trial<\/p>\n

Kwon JS, McTaggart-Cowan H, Ferguson SE, Samouelian V, Lambaudie E, Guyon F, Tidy J, Williamson K, Gleeson N, de Kroon C, van Driel W, Mahner S, Hanker L, Goffin F, Berger R, Eyjolsdottier B, Kim JW, Brotto LA, Pataky R, Yeung SST, Chan KKW, Cheung MC, Ubi J, Tu D, Sheperd L, Plante M<\/p>\n

J Gynecol Oncol, 2024 Nov;35(6):e117
Published online: Oct 18, 2024
https:\/\/doi.org\/10.3802\/jgo.2024.35.e117<\/a><\/p>\n

 <\/p>\n

Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG\/CCTG CX.5\/SHAPE Trial Comparing Simple Versus Radical Hysterectomy<\/p>\n

Ferguson SE, Brotto LA, Kwon J, Samouelian V, Ferron G, Maulard A, Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjolsdottier B, Kim JW, Gleeson N, Tu D, Sheperd L, Plante M<\/p>\n

JCO 43, 167-179(2025).Published 01.10.2024
DOI:10.1200\/JCO.24.00440<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.6″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

CORSETT<\/h3>\n

Fertility\u2010Sparing Surgery, Treatment Strategies and Survival of Women With Malignant Ovarian Germ Cell Tumours\u2014A Descriptive Analysis of the Arbeitsgemeinschaft f\u00fcr Gyn\u00e4kologische Onkologie CORSETT Database<\/p>\n

Klar M, Moubarak M, Harter P, Heitz F, Kommoss S, Grube M, Hartkopf AD, Roser E, Sehouli J, Braicu EI, Czogalla B, Burges A, Bossart M, Staebler A, Mayr D, Buderath P, Ihorst G, Hasanov MF, Link T, Hasenburg A<\/p>\n

Journal of Surgical Oncology, 2026; 1\u20138\u00a0
https:\/\/doi.org\/10.1002\/jso.70199Digital Object Identifier<\/a> (DOI)<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”transS” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Trials with translational focus<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-TR 1<\/h3>\n

Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO TR-1)<\/p>\n

Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marm\u00e9 F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kr\u00f6ber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunh\u00f6ffer T, Krockenberger M, Brucker SY, N\u00fcrnberg P, Thiele H, Altm\u00fcller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R<\/p>\n

PLoS ONE 12(10):e0186043, Published: October 20, 2017<\/p>\n

https:\/\/doi.org\/10.1371\/journal.pone.0186043<\/a><\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: Results of the observational AGO-TR 1 study (NCT02222883)<\/p>\n

Hauke J, Hahnen E, Schneider S, Reuss A, Richters LK, Kommoss S, Heimbach A, Marm\u00e9 F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, de Gregorio N, N\u00fcrnberg P, El-Balat A, Thiele H, Hilpert F, Altm\u00fcller J, Meier W, Kimmig R, Dietrich D, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Hanker LC, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P<\/p>\n

J Med Genet epub agead of print: April 2019<\/p>\n

doi:10.1136\/ jmedgenet-2018-105930[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial<\/p>\n

Schouten PC, Richters L, Vis DJ, Kommoss S, van Dijk E, Ernst C, Kluin RJC, Marm\u00e9 F, Lips EH, Schmidt S, Scheerman E, Prieske K, van Deurzen CHM, Burges A, Ewing-Graham PC, Dietrich D, Jager A, de Gregorio N, Hauke J, du Bois A, Nederlof PM, Wessels LF, Hahnen E, Harter P, Linn SC, Schmutzler RK<\/p>\n

Clin Cancer Res. 2021 Dec 1;27(23):6559-6569
doi: 10.1158\/1078-0432.CCR-21-1673
Epub 2021 Sep 30<\/p>\n

[\/et_pb_text][et_pb_divider divider_position=”center” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.17.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1\/2: results of the observational AGO-TR1 study (NCT02222883)<\/p>\n

Hauke J, Harter P, Ernst C, Burges A, Schmidt S, Reuss A, Borde J, de Gregorio N, Dietrich D, El-Balat A, Kayali M, Gevensleben H, Hilpert F, Altm\u00fcller J, Heimbach A, Meier W, Schoemig-Markiefka B, Thiele H, Kimmig R, N\u00fcrnberg P, Kast K, Richters L, Sehouli J, Schmutzler RK, Hahnen E<\/p>\n

J Med Genet. 2022 Mar;59(3):248-252.
doi: 10.1136\/jmedgenet-2020-107353. Epub 2020 Dec 3.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”qs-ovar” _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

QS-OVAR<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Therapy of advanced ovarian cancer in Germany: What is the impact of participation in clinical trials?<\/h3>\n

Results of a survey by the ORGANKOMMISSION OVAR of the Working Group on Gynecological Oncology (AGO) in the German Society of Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG)<\/p>\n

A. du Bois, J. Pfisterer, Lenka Kellermann, R. Kreienberg<\/p>\n

Geburtsh Frauenheilk 2001; 61: 863-871 \u00a9 Thieme Verlag Stuttgart – New York – ISSN 0016-5751<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” width=”100%” global_colors_info=”{}”]<\/p>\n

QS-OVAR 2001<\/h3>\n

The Quality Assurance Program of the AGO Organkommission OVAR (QS-OVAR): Care Structure and Reality in Germany 2001.<\/p>\n

Analysis of the care structure and quality of ovarian cancer therapy in Germany. Examination of the extent to which the therapy guidelines are implemented, and description of prognostic factors.<\/p>\n

A. du Bois, J. Rochon, C. Lamparter, J. Pfisterer<\/p>\n

Zentralbl Gynakol 2005; 127: 9\u201317 \u00b7 \u00a9 J. A. Barth Verlag in Georg Thieme Verlag KG DOI 10.1055\/s-2005-836289 ISSN 0044-4197<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

What influence do clinic characteristics have on prognosis in ovarian cancer in Germany?<\/h3>\n

Analysis of the association between clinic characteristics on treatment quality and outcomes in ovarian cancer in Germany.<\/p>\n

A. du Bois, J. Rochon, C. Lamparter, J. Pfisterer f\u00fcr die AGO Organkommission OVAR<\/p>\n

Zentralbl Gynakol 2005; 127: 18\u201330 \u00b7 \u00a9 J. A. Barth Verlag in Georg Thieme Verlag KG DOI 10.1055\/s-2005-836290 ISSN 0044-4197<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.21.0″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO-Study Group<\/h3>\n

Wimberger P, Pfisterer J, du Bois A, Hilpert F, Kerkmann M, Sehouli J, Mahner S, de Gregorio N, Hanker L, Heitz F, Marm\u00e9 F, W\u00f6lber L, Holtmann L, Elser G, Harter P<\/p>\n

International Journal of Gynecologic Cancer 2023;33:1083-1089
Published Online First: 31 March 2023. doi: 10.1136\/ijgc-2022-004233<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group \u2013 Real-world observations<\/h3>\n

Wimberger P, Pfisterer J, du Bois A, Hilpert F, Kerkmann M, Sehouli J, Mahner S, de Gregorio N, Hanker LC, Heitz F, Marm\u00e9 F, W\u00f6lber L, Holtmann L, Elser G, Harter P, for the AGO Study Group<\/p>\n

European Journal of Surgical Oncology, Vol 51 (2025) , Issue 6, 109696<\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”sonstige” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Other publications<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Advanced epithelial ovarian cancer: 1998 consensus statement<\/h3>\n

J.S. Berek, K. Bertelsen, A. du Bois, M.F. Brady, J. Carmichel, E.A. Eisenhauer, M. Gore, S. Grenman, T.C. Hamilton, S. W. Hansen, P.G. Harper, G. Horvath, S.B. Kaye, H.J. L\u00fcck, B. Lund, W.P. McGuire, J.P. Neijt, R.F. Ozols, M.K.B. Parmar, M.J. Piccart-Gebhart, R. van Rijswijk, P. Rosenberg, G.J.S. Rustin, C. Sessa, J.T. Thigpen, C. Trop\u00e9, M.K. Tuxen, I. Vergote, J.B. Vermorken, & P.H.B. Willemse<\/p>\n

Ann Oncol 10 (suppl. 1): S87-S92 (1999)[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Is efficient clinical research in gynecologic oncology possible in Germany<\/h3>\n

History and current status using the AGO ovarian cancer trials as an example. A statement of the AGO Ovarian Cancer Study Group.<\/p>\n

du Bois A, Studiengruppe Ovarialkarzinom der Arbeitsgemeinschaft gyn\u00e4kologische Onkologie (AGO)<\/p>\n

Forum DKG 14: 815-824 (1999)<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Undergoing Platinum\/Paclitaxel-Containing First-Line Chemotherapie:<\/h3>\n

An Exploratory Analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group<\/p>\n

Christina Fotopoulou, Andreas du Bois, Alexandros N. Karavas, Ralf Trappe, Behnaz Aminossadati, Barbara Schmalfeldt, Jacobus Pfisterer and Jalid Sehouli<\/p>\n

J Clin Oncol 26 (16): 2683-2689[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 3\/QoL<\/h3>\n

Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin\/Paclitaxel Versus Carboplatin\/Paclitaxel<\/p>\n

Elfriede R. Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, Felix Hilpert, Fedor Daghofer and Andreas du Bois<\/p>\n

J Clin Oncol 24 (4): 579-586[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 3 \/ Her-2\/neu<\/h3>\n

Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)\/neu in Patients With Advanced Ovarian Cancer Treated With Platinum\/Paclitaxel as First Line Chemotherapy. A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO-OVAR Germany<\/p>\n

Pfisterer J, du Bois A, Bentz EK, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F<\/p>\n

Int J Gynecol Cancer 2009; 19:109-115[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 14<\/h3>\n

Non-enrollment of ovarian cancer patients in clinical trials: Reasons and Backgrounds<\/p>\n

Harter P, du Bois A, Schade-Brittinger C, Burges A, Wollschlaeger K, Gropp M, Schmalfeldt B, Huober J, Staehle A, Pfisterer J for the Study Coordination Group of the AGO-OVAR<\/p>\n

Ann Oncol 16: 1801-1805, 2005[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Neurotox<\/h3>\n

Neuroprotection with amifostine in the 1st-line treatment of advanced ovarian cancer with carboplatin\/paclitaxel-based chemotherapy – a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group<\/p>\n

Hilpert F, St\u00e4hle A, Tom\u00e9 O, Burges A, Rossner D, Sp\u00e4the K, Heilmann V, Richter B and du Bois A for the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) ovarian cancer study group<\/p>\n

Support Care Cancer 2005 Oct; 13(10): 797-805[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer<\/h3>\n

Mackay H J, Brady M F, Oza A M, Reuss A, Pujade-Lauraine E, Swart A M, Siddiqui N, Colombo N, Bookman M A, Pfisterer J, du Bois A on behalf of the Gynecologic Cancer InterGroup (2010)<\/p>\n

Int J Gynecol Cancer 20:945-952;2010[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

European network of gynaecological oncological trial groups’ requirements for trials between academic groups and pharmaceutical companies<\/h3>\n

Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee AGJ, du Bois A<\/p>\n

Int J Gynecol Cancer 20:476-478;2010[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

CA125 Early decline as a surrogate for progression-free survival in recurrent ovarian cancer<\/h3>\n

Lee CK, Friedlander M, Brown Ch, Gebski V, Georgopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza Mr, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes J<\/p>\n

J Natl Cancer Inst 2011;103:1-5[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to Carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial<\/h3>\n

Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Bomann K, Sugimoto A, Vaughan M, Reinthaller A, Vergote I, Ferrandina G, Dell’Anna T, Huober J, Pujade-Lauraine E<\/p>\n

Gyn Oncol 2011;122(2):226-32[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a GCIG CALYPSO sub-study<\/h3>\n

Kurtz JE, Kaminski MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E on Behalf of Gynecologic Cancer Intergroup<\/p>\n

Ann Oncol 2011 (Epub ahead of print)[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

The European network of Gynaecological Oncological Trial Groups<\/h3>\n

Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Ottevanger N, del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, Van der Zee AGJ, du Bois A<\/p>\n

Clin.Invest. (2012) 2(1), 35-37[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Treatment of Elderly Ovarian Cancer Patients in the Context of Controlled Clinical Trials: A Joint Analysis of the AGO Germany Experience<\/h3>\n

Hilpert F, Wimberger P, du Bois A, Pfisterer J, Harter P<\/p>\n

Onkologie 2012;35:76\u201381[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Roadmap for the European Network of Gynaecological Trial Groups (ENGOT) Trials<\/h3>\n

Ignace Vergote, MD, PhD, Gabriele Elser, RN, Benedicte Votan, MSc, Laura Farrelly, BSc(hons), RN, Joke De Roover, PhD, Jane Bryce, RN, MSN, Andreas du Bois, MD, PhD, and On Behalf of the member trial groups of the European Network of Gynaecological Trial groups (ENGOT)<\/p>\n

Int J Gynecol Cancer 2013;23: 1339-1343[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Specialized Pathology Review in Patients With Ovarian Cancer, Results From a Prospective Study<\/h3>\n

Stefan Kommoss, MD, Jacobus Pfisterer, MD, Alexander Reuss, MSc, Joachim Diebold, MD, Steffen Hauptmann, MD, Christine Schmidt, MD, Andreas du Bois, MD, Dietmar Schmidt, MD, and Friedrich Kommoss, MD<\/p>\n

Int J Gynecol Cancer 2013;23: 1376-1382[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: A sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT Study<\/h3>\n

Trillsch F, Mahner S, Woelber L, Vettarazzi E, Reiss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik DM, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schr\u00f6der W, M\u00fcnstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A<\/p>\n

Annals of Oncology 25:1320-1327.2014[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients<\/h3>\n

Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J.<\/p>\n

Eur J Cancer. 2015.2015 May;51(7):825-32[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

The European Network for Gynaecological Oncological Trial Groups Charta for Privilegded Partnership<\/h3>\n

Marth C, du Bois A (ENGOG), Schauer C, du Bois A (AGO Study Group), Casado A, Vergote I, del Campo J, Goudopoulou A,
\nPujade-Lauraine E, Bruchim I, Colombo N, Pignata S, Ledermann J, Glasspool R, Taskiran C, Fehr M, Cibula D<\/p>\n

Int J Gynecol Cancer 2015;25: 1094-1095[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

European Network of Gynaecological Oncological Trial Groups\u2019 Requirements for Trials Between Academic Groups and Industry Partners \u2013 First Update 2015<\/h3>\n

du Bois A, Reuss A, Pujade-Lauraine E, Pignata S, Ledermann J, Casado A, Sehouli J, Mirza M, Colombo N, Marth C, Witteveen E, del
\nCampo J, Calvert P, Aravantinos G, Vardar AM, van der Zee AGJ, Korach J, Taskiran C, Fehr M, Glasspool R, Pfisterer J, Cibula D, Vergote I and on behalf of the member trial groups of the European Network of Gynaecological Oncological Trial Groups (ENGOT)<\/p>\n

Int J Gynecol Cancer 2015; Jun 9 Epub ahead of print[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group ROBOT-Study<\/h3>\n

Farthmann J, Hasenburg A, Weil M, Fotopoulou C, Ewald-Riegler N, du Bois O, Trillsch F, Mahner S, Strauss H-G, Wimberger P, Reuss A, du Bois A<\/p>\n

Support Care Cancer, 23(1), 117-23[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarib treatment of ovarian cancer patients<\/h3>\n

Bachmann HS, Meier W, du Bois A, Kimmig R, Kuhlmann JD, Siffert W, Sehouli J, Wollschlaeger K, Huober J, Hillemanns P, Burges A, Schmalfeldt B, Aminossadati B, Wimberger P<\/p>\n

Br J Clin Pharmacol 2015 Nov; 80(5):1139-48. doi: 10.1111\/bcp.12688. Epub 2015 Jul 22[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group Metadatabase<\/h3>\n

Grabowski J, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, Ray-Coquard I, Heitz J, Traut A, Pfisterer J, du Bois A<\/p>\n

Gynecol Oncol 2016 Jan 22. pii: S0090-8258(16)30020-8. doi: 10.1016\/j.ygyno.2016.01.022. Epub ahead of print[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer<\/h3>\n

P. Harter, A. du Bois, S. Mahner, J. Pfisterer, O. Ortmann, C. Marth, D. Fink, F. Hilpert, U. Wagner, J. Sehouli<\/p>\n

Geburtsh Frauenheilk 2016; 76: 147-149[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO<\/h3>\n

Klar M, Hasenburg A, Hasanov M, Hilpert F, Meier W, Pfisterer J, Pujade-Lauraine E, Herrstedt J, Reuss A, du Bois A<\/p>\n

European Journal of Cancer: Volume 66, October 2016, Pages 114-124
https:\/\/www.ejcancer.com\/article\/S0959-8049(16)32316-4\/fulltext<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial<\/h3>\n

F. Trillsch, S. Mahner, F. Hilpert, L. Davies, E. Garc\u00eda-Mart\u00ednez, G. Kristensen, A. Savarese, P, Vuylsteke, M. Los, F. Zagouri, L. Gladieff, J. Sehouli, C. Khoon Lee, V. Gebski & E. Pujade-Lauraine<\/p>\n

Annals of Oncology 27: 1733-1739, 2016
\ndoi.10.1093\/annonc\/mdw236
\nPublished online 10 June 2016[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Better resource utilization and quality of care for ovarian cancer patients using internet-based pathology review<\/h3>\n

Kommoss S, Kommoss F, Diebold J, Lax S, Schmid D, Staebler A, du Bois A, Pfisterer J<\/p>\n

British Journal of Cancer 116, 287-292 (31 January 2017)<\/p>\n

doi:10.1038\/bjc.2016.416[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer<\/h3>\n

King MT, Stockler MR, O’Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigau D, Costa DSJ, Friedlander ML for the GCIG Symptom Benefit group<\/p>\n

Qual Life Res (2018) 27: 59-74<\/p>\n

https:\/\/doi.org\/10.1007\/s11136-017-1729-8<\/a>, online first 16.12.2017<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions<\/h3>\n

Winterhoff B, Kommoss S, Heitz F, Konecny GE, Dowdy SC, Mullany SA, Park-Simon TW, Baumann K, Hilpert F, Brucker S, du Bois A, Schr\u00f6der W, Burges A, Shen S, Wang J, Tourani R, Ma S, Pfisterer J and Aliferis CF<\/p>\n

AMIA Annu Symp Proc. 2018: 1093-1102. Published 2018 Dec 5.<\/p>\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6371365\/<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

The end of systematic lymphonodectomy in advanced ovarian cancer<\/h3>\n

A. Schnelzer, T. Fehm, C. Jackisch f\u00fcr die AGO-Studiengruppe<\/p>\n

JOURNAL ONKOLOGIE 1\/2020<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.19.1″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study<\/h3>\n

Lee YC, King MT, O\u2019Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann J, Berton-Rigaud D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML, for the GCIG-Symptom Benefit Group<\/p>\n

Int J Gynecol Cancer 2022;32:761\u2013 768<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Oncological Outcomes of Patients with Cervical Cancer after Fertility Sparing Treatment \u2013 FERTISS Retrospective Multicenter Trial<\/h3>\n

Sl\u00e1ma J, Runnebaum IB, Scambia G, Angeles Fite M, Bahrehmand K, Kommoss S, Fagotti A, Narducci F, Matylevich O, Holly J, Martinelli F, Koual M, Samokhvalova O, El-Balat A, Corrado G, C\u0103p\u00eelna ME, Schr\u00f6der W, Nov\u00e0k N, Shushkevich A, Fricov\u00e1 L, Cibula D<\/p>\n

Am J Obstet Gynecol. Volume 228, Issue 4,2023, Pages 443.e1-443.e10,
https:\/\/doi.org\/10.1016\/j.ajog.2022.11.1295<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer<\/h3>\n

Philipp Harter, Gerhard Bogner, Luis Chiva, David Cibula, Nicole Concin, Christina Fotopoulou, Antonio Gonzalez-Martin, Frederic Guyon, Viola Heinzelmann-Schwarz, Frederic Kridelka, Sven Mahner, Frederik Marm\u00e9, Christian Marth, Philippe Morice, Zolt\u00e1n Nov\u00e1k, Andrea Papadia, Isabelle Ray-Coquard, Mikul\u00e1\u0161 Redecha, Andres Redondo, Richard Schwameis, Jalid Sehouli, Manuela Undurraga, Toon Van Gorp, Ignace Vergote<\/p>\n

Bull Cancer. 2023 Mar 24; S0007-4551(23)00098-X.
doi: 10.1016\/j.bulcan.2023.02.011.<\/p>\n

Epub ahead of print<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Treatment and survival of patients with malignant ovarian sex cord\u2010stromal cell tumours: An analysis of the Arbeitsgemeinschaft f\u00fcr Gyn\u00e4kologische Onkologie (AGO) study group CORSETT database<\/h3>\n

Klar M, Plett H, Harter P, Heitz F, Kommoss S, Hartkopf AD, Grube M, Roser E, Sehouli J, Braicu I, Czogalla B, Burges A, Bossart M, Hasanov MF, Link T, Staebler A, Mayr D, Buderath P, Hasenburg A<\/p>\n

J Surg Oncol. 2023;1\u20108. doi:10.1002\/jso.27248<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.20.2″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients<\/h3>\n

Richter R, Armbrust R, Woopen H, Hilpert F, Harter P, Sehouli J<\/p>\n

ESMO Open 2021 April; 6(2); 100081.
Published online: Jun 24, 2021.
https:\/\/doi.org\/10.1016\/j.esmoop.2021.100176<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.20.2″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.21.0″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Psychische Belastung und deren Einflussfaktoren bei \u00dcberlebenden von malignen ovariellen Keimzell- oder Keimstrangstromatumoren \u2013 eine Analyse der AGO-CORSETT-Datenbank<\/h3>\n

Bossart M, Plett H, Kr\u00e4mer B, Braicu E, Czogalla B, Klar M, Singer S, Mayr D, Staebler A, du Bois A, Kommoss S, Link T, Burges A, Heitz F, Grube M, Trillsch F, Harter P, Wimberger P, Buderath P, Hasenburg A<\/p>\n

Onkologie 2023 \u00b7 29:447\u2013454 https:\/\/doi.org\/10.1007\/s00761-023-01334-9 <\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.20.2″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.0″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Reproductive outcomes after fertility-sparing surgery for cervical cancer – results of the multicenter FERTISS study<\/h3>\n

Fricov\u00e1 L, Kommoss S, Scambia G, Ferron G, Koci\u00e1n R, Harter P, Anchora LP, Bats AS, Nov\u00e0k Z, Walter CB, Raspagliesi F, Lambaudie E, Bahrehmand K, Andress J, Kl\u00e1t J, Pasternak J, Matylevich O, Szeterlak N, Min\u00e1\u0159 L, Heitz F, C\u0103p\u00eelna ME, Runnebaum I, Cibula C, Sl\u00e1ma J<\/p>\n

Gynecologic Oncology 2024, Volume 190, 179 \u2013 185,
DOI: 10.1016\/j.ygyno.2024.08.020\u00a0<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.20.2″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

How long is long enough?<\/h3>\n

An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes<\/p>\n

Haggstrom L, Lee YC, Scott C, Harter P, Woelber L, Ledermann J, Gourley C, McNeish IA, Amant F, Ray-Coquard I, Leary A, Oza AM, Tinker A, Gonz\u00e1lez-Martin A, Cecere SC, Pignata S, Colombo N, Yoshida H, Marth C, Rosengarten O, Moore KN, G\u00f3mez-Garc\u00eda EM, Tan D, Friedlander ML<\/p>\n

Int J Gynecol Cancer .\u00a02024 Dec 2;34(12):1932-1939. doi:10.1136\/ijgc-2024-005976<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.20.2″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

QS-CX met<\/h3>\n

Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study
A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus<\/p>\n

Denschlag D, Czogalla B, Heitz F, Kerkmann M, Fangmann LC, Klecker PH, Stuebs FA, W\u00f6lber L, Radosa J, Lodde PC, Seitz S, George C, Mach P, Fink A, Bokhua D, deGregorio N, Lampe B, Hemptenmacher F, Friebe V, Fleisch M, Wimberger P, Jaeger A, Schnelzer A, Mittelstadt S, Ratiu D, Eichbaum M, Haus A, Kalder M, Ataseven B, Schr\u00f6der W, Bronger H, Kosse J, Ulrich UA, Elser G, Harter P.<\/p>\n

Geburtshilfe Frauenheilkd. 2025 May 15;85(5):520-532.
doi: 10.1055\/a-2520-5736<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”gcig” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

GCIG Rare Tumor Working Group – publications<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”gcig” _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”18px” header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Ovarian cancer<\/h3>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)<\/h3>\n

Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, Mezzanzanica D, Quinn M, Maenpaa J, Kim JW, Mahner S, Hilpert F, Baumann K, Pfisterer J, du Bois A.<\/p>\n

Int J Gynecol Cancer. 2014 Nov; 24:S5-S8[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer Inter Group (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas<\/h3>\n

Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, Maenpaa J, Kim JW, Pujade-Lauraine E, Glasspool RM, Ray-Coquard I, Gershenson D.<\/p>\n

Int J Gynecol Cancer. 2014 Nov; 24:S9-S13[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma<\/h3>\n

Ledermann JA, Luvero D, Shafer A, O’Connor D, Mangili G, Friedlander M, Pfisterer J, Mirza MR, Kim JW, Alexandre J, Oza A, Brown J.<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S14-S19[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary<\/h3>\n

Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzanzanica D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A.<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S20-S25[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary<\/h3>\n

Glasspool RM, Gonz\u00e1les Mart\u00edn A, Millan D, Lorusso D, \u00c5vall-Lundquvist E, Hurteau JA, Davis A, Hilpert F, Kim JW, Alexandre J, Ledermann JA.<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S26-S29[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers<\/h3>\n

Reed NS, Pautier P, \u00c5vall-Lundqvist E, Choi CH, du Bois A, Friedlander M, Fyles A, Kichenadasse G, Provencher DM, Ray-Coquard I.<\/p>\n

Int J Gynecol Cancer. 2014 Nov; 24:S30-S34[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary<\/h3>\n

Reed NS, Gomez-Garcia E, Gallardo-Rincon D, Barrette B, Baumann K, Friedlander M, Kichenadasse G, Kim JW, Lorusso D, Mirza MR, Ray-Coquard I.<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S35-S41[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors<\/h3>\n

Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N.<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S42-S47[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors<\/h3>\n

Brown J, Friedlander M, Backes FJ, Harter P, O’Connor DM, die la Motte Rouge T, Lorusso D, Maenpaa J, Kim JW, Tenney ME, Seckl MJ[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions<\/h3>\n

Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RL, Casado Herr\u00e1ez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K, participants of the 5th Ovarian Cancer Consensus Conference<\/p>\n

Ann Oncol 2017 Apr 1;28(4):711-717[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Individualized Therapy and Patient Factors<\/h3>\n

McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K; on behalf of the participants of the 5th Ovarian Cancer Consensus Conference<\/p>\n

Ann Oncol 2017 Apr 1;28(4):702-710[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease<\/h3>\n

Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zhang R, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference<\/p>\n

Ann Oncol 2017 Apr 1;28(4):727-732[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Clinical trial design for rare ovarian tumours<\/h3>\n

Leary AF, Quinn M, Fujiwara K, Coleman RL, Kohn E, Sugiyama T, Glasspool R, Ray-Coquard I, Colombo N, Bacon M, Zeimet A, Westermann A, Gomez-Garcia E, Provencher D, Welch S, Small W, Millan D, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference<\/p>\n

Ann Oncol 2017 Apr 1;28(4):718-726[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.17.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

6th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup<\/h3>\n

Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, NcNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan David SP, Colombo N, Zang R, Concin N, O\u2019Donnell, Rauh-Hain A, Herrington S, Marth C, Poveda A, Fujiwara K, Stuart GC, Oza AM, Bookman M on behalf of the participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research<\/p>\n

Lancet Oncol 2022; 23: e374\u201384<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting<\/h3>\n

Sehouli J, Boer J, Brand AH, Oza A, O\u2018Donnell J, Bennett K, Glaspool R, Lee C, Ethier JL, Harter P, Seebacher-Shariat V, Chang TC, Cohen PA, Van Gorp T, Chavez-Blanco A, Welch S, Hranovska H, O\u2019Toole S, Lok C, Madariaga A, Rauh-Hain JA, Perez Fidalgo A, Tan D, Michels J, Pothuri B, Fujiwara N, Rosengarten O, Nishio H, Kim SI, Mukopadhyay A, Piovano E, Cecere SC, Kohn EC, Mukherjee U, Nasser S, Lindemann K, Croke J, Chen X, Geissler F, Bookman MA<\/p>\n

Int J Gynecol Cancer 2024;34:1677-1684<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”gcig” _builder_version=”4.16″ _module_preset=”default” custom_padding=”20px||0px||false|false” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”18px” header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Carcinosarcoma of the uterus and ovary<\/h3>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma<\/h3>\n

Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S55-S60[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas<\/h3>\n

Hensley ML, Barette BA, Baumann K, Gaffney D, Hamilton AL, Kim JW, Maenpaa JU, Pautier P, Siddiqui NA, Westermann AM, Ray-Coquard I.<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S61-S66[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”gcig” _builder_version=”4.16″ _module_preset=”default” custom_padding=”20px||0px||false|false” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”18px” header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Endometrial and cervical carcinomas<\/h3>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma<\/h3>\n

Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B.<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S67-S72[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus<\/h3>\n

Pautier P, Nam EJ, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray-Coquard I.<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S73-S77[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract<\/h3>\n

Friedlander ML1, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P.<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S78-S82[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma<\/h3>\n

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr.<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S83-S89[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix<\/h3>\n

Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glaspool RM, Devouassoux-Shisheboran M, Covens A, Lorusso D, Kurzeder C, Kim JW, Gladieff L, Bryce J, Friedlander M, Fujiwara K<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S90-S95[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma<\/h3>\n

Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S96-S101[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix<\/h3>\n

Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, \u00c5vall-Lundqvist E, Pautier P, Reed NS, Fujiwara K.<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S102-S108[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

The Gynecologic Cancer InterGroup (GCIG) consensus recommendations for clinical research in Endometrial Cancer<\/h3>\n

Creutzberg C L, Kim JW, Eminowicz G, Allanson E, Eberst L, Kim SI, Nout RA, Park jY, Lorusso D, Mileshkin L, Ottevanger PB, Brand A, Mezzanzanica D, Oza A, Gebski V, Pothuri B, Batley T, Gordon C, Mitra T, White H, Howitt B, Matias-Guiu X, Ray-Coquard I, Gaffney D, Small W, Miller A, Concin N, Powell MA, Stuart G, Bookman MA on behalf of the participants of the 2023 Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research<\/p>\n

The Lancet Oncology,Vol 25, Issue 9, 2024,pp e420-e431
https:\/\/doi.org\/10.1016\/S1470-2045(24)00192-X<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner module_id=”gcig” _builder_version=”4.16″ _module_preset=”default” custom_padding=”20px||0px||false|false” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”18px” header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Other rare gynecologic tumors<\/h3>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup<\/h3>\n

Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, Ngan HY, Golfier F, Sekharan PK, Charry RC, Poveda A, Kim JW, Xiang Y, Berkowitz R, Seckl MJ<\/p>\n

Int J Gynecol Cancer. 2014 Nov;24:S109-S116[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.2em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas<\/h3>\n

Leitao MM Jr, Cheng X, Hamilton AL, Siddiqui NA, Jurgenliemk-Schulz I, Mahner S, \u00c5vall-Lundqvist E, Kim K, Freyer G.<\/p>\n

Int J Gynecol Cancer. 2014; Nov24:S117-S122[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_sidebar area=”et_pb_widget_area_1″ show_border=”off” admin_label=”Seitenleiste” _builder_version=”4.16″ header_text_color=”#000000″ body_font=”|700|||||||” body_text_color=”#ef5b21″ background_color=”rgba(255,255,255,0.6)” background_enable_color=”off” min_height=”257px” custom_padding=”8%|4%|4%|8%|false|false” saved_tabs=”all” global_colors_info=”{}”][\/et_pb_sidebar][\/et_pb_column][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Primary Therapy | Relapse Therapy | Uterus | Vulva | Cervix | Surgical Issues | Translational Focus | QS-Ovar |Other Publications | GCIG Rare Tumor Working GroupPublished TrialsPrimary diseaseAGO-OVAR 1\/2 Phase I\/II study of the combination of carboplatin and paclitaxel as first-line therapy patients with advanced epithelial ovarian cancer A. du Bois, H.-J. L\u00fcck, T. […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":792,"menu_order":70,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-844","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/comments?post=844"}],"version-history":[{"count":87,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/844\/revisions"}],"predecessor-version":[{"id":2515,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/844\/revisions\/2515"}],"up":[{"embeddable":true,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/792"}],"wp:attachment":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/media?parent=844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}